Clinical Trials Logo
  1. Home
  2. Nausea and Vomiting
  3. NCT01275664

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Nausea and Vomiting Clinical Trial

Official title:
Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy

Clinical Trial Summary

This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the frequency of chemotherapy-induced nausea and vomiting based on complete response (no vomiting and no use of rescue therapy) during the 6 days following intraperitoneal (IP) chemotherapy for the 3-day regimen of aprepitant (both injection and capsules) in combination with granisetron transdermal system and dexamethasone in ovarian cancer patients receiving IP cisplatin OR IP carboplatin.

SECONDARY OBJECTIVES:

I. To evaluate possible endpoints for the chemotherapy-induced nausea and vomiting, including:

- Functional Living Index-Emesis (FLIE) questionnaire scores

- Mean vomiting, nausea and total FLIE scores and changes from baseline in FLIE scores

- Percentages of patients with no impact on daily living (NIDL), i.e. > 108/126 total FLIE score II. To describe the timing of nausea and vomiting that may guide modifications to the standard regimen.

OUTLINE: This is a multicenter study.

Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone orally (PO) on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.

Patients complete the Functional Living Index--Emesis (FLIE) and a symptom diary at baseline and on days 3 and 6. ;

Study Design

Related Conditions & MeSH terms

  • Adenocarcinoma
  • Brenner Tumor
  • Carcinoma
  • Carcinoma, Endometrioid
  • Cystadenocarcinoma
  • Fallopian Tube Neoplasms
  • Nausea
  • Nausea and Vomiting
  • Ovarian Brenner Tumor
  • Ovarian Clear Cell Cystadenocarcinoma
  • Ovarian Endometrioid Adenocarcinoma
  • Ovarian Mucinous Cystadenocarcinoma
  • Ovarian Neoplasms
  • Ovarian Seromucinous Carcinoma
  • Ovarian Serous Cystadenocarcinoma
  • Peritoneal Neoplasms
  • Stage II Ovarian Cancer
  • Stage IIA Fallopian Tube Cancer
  • Stage IIA Ovarian Cancer
  • Stage IIB Fallopian Tube Cancer
  • Stage IIB Ovarian Cancer
  • Stage IIC Fallopian Tube Cancer
  • Stage IIC Ovarian Cancer
  • Stage IIIA Fallopian Tube Cancer
  • Stage IIIA Ovarian Cancer
  • Stage IIIA Primary Peritoneal Cancer
  • Stage IIIB Fallopian Tube Cancer
  • Stage IIIB Ovarian Cancer
  • Stage IIIB Primary Peritoneal Cancer
  • Stage IIIC Fallopian Tube Cancer
  • Stage IIIC Ovarian Cancer
  • Stage IIIC Primary Peritoneal Cancer
  • Stage IV Fallopian Tube Cancer
  • Stage IV Ovarian Cancer
  • Stage IV Primary Peritoneal Cancer
  • Undifferentiated Ovarian Carcinoma
  • Vomiting
Clinical Trial Details
NCT number NCT01275664
Study type Interventional
Source Gynecologic Oncology Group
Contact
Status Terminated
Phase N/A
Start date June 2011
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05016180 - Effect of Ultrasound-guided Transversus Abdominis Plane Block After Laparoscopic Bariatric Surgery Phase 2
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Withdrawn NCT00891761 - A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy Phase 3
Completed NCT05533281 - Efficacy of Three Antiemetics in Preventing Nausea and Vomiting Phase 4
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Completed NCT00293384 - Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant N/A
Completed NCT00006348 - Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Phase 3
Completed NCT00004895 - Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Phase 2
Completed NCT00003817 - Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy Phase 2
Active, not recruiting NCT06045364 - Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation Phase 1/Phase 2
Completed NCT00978185 - Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy Phase 3
Completed NCT00064272 - UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer Phase 2
Completed NCT00003213 - Drugs to Reduce the Side Effects of Chemotherapy Phase 3
Recruiting NCT05690802 - The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV N/A
Recruiting NCT06314906 - Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer Phase 3
Completed NCT00590317 - Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department Phase 2
Completed NCT03185156 - The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate Phase 4
Not yet recruiting NCT06382012 - Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Phase 2/Phase 3
Completed NCT01590147 - Supportive Intervention Programs Study N/A
Completed NCT00381862 - Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting Phase 2